Untitled

Polycystic Kidney Disease and Related Inherited Disorders of Tubule Growth and Development

  • Overview

    • Polycystic kidney diseases (PKD) are a genetically heterogeneous group and a leading cause of kidney failure.
    • Autosomal dominant PKD (ADPKD) is the most common life-threatening monogenic disease, affecting 12,000,00012{,}000{,}000 people worldwide.
    • Autosomal recessive PKD (ARPKD) is rarer but predominantly affects the pediatric population.
    • Cyst formation occurs in a wide range of syndromic diseases; defects in primary cilia function or structure define ciliopathies, many with kidney cysts as a common phenotype.
    • Inherited diseases commonly associated with a cystic phenotype are summarized in Table 327-1 (in the transcript): major diseases include ADPKD, ADPKD-like, ARPKD, autosomal dominant tubulointerstitial kidney disease (ADTKD), renal cysts with diabetes syndrome, nephronophthisis (NPHP), Senior–Loken syndrome, Leber congenital amaurosis, Meckel–Gruber syndrome, Bardet–Biedl syndrome, Oral-facial-digital syndrome type I (OFD1), tuberous sclerosis (TS), Von Hippel–Lindau disease (VHL), and CAKUT-related conditions.

  • Key concepts: ciliopathies and disease genes

    • Primary cilium defects (structure or function) underlie ciliopathies; ciliopathies often present with kidney cysts among other organ involvement.
    • Core ADPKD genes: PKD1 and PKD2, encoding polycystin-1 (PC1) and polycystin-2 (PC2).
    • PC1 is a large 11-transmembrane GPCR-like protein; PC2 is a calcium-permeable 6-transmembrane TRP channel.
    • PC1 and PC2 are widely expressed; PC1 is developmentally high and decreases in adulthood, PC2 is relatively constant.
    • PC1/PC2 localize to the primary cilium, cell membranes, and cell–cell junctions of tubular epithelial cells.
    • PC1/PC2 form a receptor–channel complex with a proposed 1:3 stoichiometry (PC1:PC2). The complex functions as a mechanosensor or chemical sensor, regulating calcium and G-protein signaling; it also influences the cell cycle, actin cytoskeleton, planar cell polarity (PCP), and cell migration.
    • Signaling pathways implicated include: Wnt, mTOR, STAT3, cMET, PI3K/Akt, GPCR, EGFR; and it can influence CFTR localization and activity.
    • A working hypothesis: loss of ciliary PC1/PC2 function leads to aberrant calcium signaling, increased adenylyl cyclase activity, and decreased phosphodiesterase activity, causing elevated cAMP, which promotes protein kinase A (PKA) activity and cyst growth via chloride and aquaporin channels in the cyst-lining cells of ADPKD kidneys.

  • Detailed genetic and molecular biology (ADPKD-focused)

    • PKD1 and PKD2 gene details
    • PKD1: approximately 4646 exons, ~52extkb52 ext{ kb} genomic DNA; produces a ~14extkb14 ext{ kb} transcript encoding polycystin-1, ~43004300 amino acids.
    • PKD2: single-copy gene with 1515 exons, producing a ~5.3extkb5.3 ext{ kb} mRNA encoding polycystin-2, ~968968 amino acids.
    • Additional ADPKD-associated genes reported in patients
    • GANAB (glucosidase IIa subunit) and DNAJB11 (BiP cofactor) affect PC1 trafficking; mutations are rare and found in only a small number of families.
    • Genotype–phenotype and mosaic/somatic second-hit model
    • In ADPKD, every cell carries a germline mutant allele in PKD1 or PKD2, but cysts arise from clonal expansion of cells with a somatic second-hit mutation in the normal allele.
    • Mouse models show that partial loss of function of the second allele in a proliferative environment suffices for cystogenesis, implying a critical threshold of PKD1 activity in a cell.
    • Somatic inactivation of PKD1 in adult mice yields slow cyst development unless a “third hit” (e.g., loss of a growth suppressor gene, activation of growth-promoting genes, or renal injury triggering developmental programs) occurs to accelerate cyst formation.
    • ADPKD pathogenesis and ciliary signaling
    • Ciliary dysfunction leads to altered calcium signaling, increased cAMP, and downstream effects on proliferation and fluid secretion in cyst-lining cells.
    • Clinical manifestations and natural history
    • Progressive bilateral renal cyst formation; focal cysts detectable early in life; by the fifth decade, kidneys commonly contain hundreds to thousands of cysts.
    • Kidneys can enlarge up to ~4× normal length and weigh up to ~20× normal.
    • Phenotype is highly variable; many individuals are asymptomatic until the 4th–5th decade.
    • Common presentations: back/ flank pain (~60%), cyst infection, cyst hemorrhage, nephrolithiasis; gross hematuria from cyst rupture occurs in ~40% of patients at some point.
    • Proteinuria is usually mild.
    • Infections: up to ~50% experience renal infection during lifetime; infected cysts and acute pyelonephritis are common.
    • Renal disease correlates with structural abnormalities; hepatic cysts (polycystic liver disease) are the most common extrarenal involvement; polycystic liver disease is distinct from autosomal dominant polycystic liver disease (ADPLD; PRKCSH, SEC63 mutations).
    • Modifier genes and phenotypes
    • GANAB and DNAJB11 mutations can yield milder cystic disease than classic ADPKD; GANAB mutations may present with ADPKD-like or ADPLD-like phenotypes; DNAJB11 mutations may present with renal fibrosis (ADTKD-like features).
    • Diagnostic approach and radiology
    • Family history compatible with autosomal dominant inheritance plus multiple kidney cysts bilaterally supports diagnosis.
    • Imaging modalities: renal ultrasonography (presymptomatic screening), CT, and MRI.
    • Diagnostic ultrasound criteria for at-risk subjects (age-stratified):
      • Ages 15–29: at least two renal cysts (unilateral or bilateral) with sensitivity extSe=96extextperthousandSpecificity=100extextperthousandext{Se} = 96 ext{ extperthousand} \text{Specificity} = 100 ext{ extperthousand}
      • Ages 30–59: at least two cysts in each kidney and at least four cysts in each kidney for age ≥60: Se = 100%, Sp = 100%.
      • Absence of at least two cysts in each kidney in ages 30–59 has 0% false negatives for disease exclusion, but PKD2-related disease can escape sensitivity due to later onset.
    • CT and T2-weighted MRI (with or without contrast): more sensitive than ultrasound; MRI with gadolinium has minimal renal toxicity but small cysts (<2–3 mm) may be undetectable; CT involves radiation risks and risk of nephrotoxicity with contrast.
    • Genetic testing: linkage analysis and mutational analyses available; PKD1 is large with highly homologous pseudogenes making analysis challenging and costly; newer technologies (paired-end NGS with long-range PCR) may reduce cost and improve sensitivity.
    • Treatment and management (ADPKD)
    • No FDA-approved therapy to prevent cyst growth or decline in renal function (as of the source).
    • Blood pressure control: target ≤ 140/90extmmHg140/90 ext{ mmHg} to reduce cardiovascular complications and slow disease progression; however, overly aggressive BP targets (e.g., systolic ~110extmmHg110 ext{ mmHg}) may reduce renal perfusion and worsen outcomes.
    • Cyst infections: treat with lipophilic antibiotics that penetrate cyst walls (e.g., trimethoprim-sulfamethoxazole, quinolones, chloramphenicol) for 4$-$6 weeks.
    • Kidney stones: standard management—analgesics and hydration; stones in ADPKD are often uric acid–dominant (>50%), with calcium oxalate stones also present; urinary acidification defects and hypocitraturia contribute to stone pathogenesis.
    • Pain management due to renal enlargement: analgesics, nonpharmacologic approaches (TENS, acupuncture, biofeedback); surgical cyst decompression in select cases.
    • Renal replacement therapy (RRT): >50% of patients eventually require peritoneal dialysis (PD), hemodialysis, or kidney transplantation; considerations include limited intra-abdominal space with massive kidneys, risk of hernia and back pain, and potential pretransplant nephrectomy for space/allograft management.
    • Targeted therapies to slow progression: major clinical trials focus on inhibiting cell proliferation and/or fluid secretion.
      • mTOR inhibitors (sirolimus, everolimus): tested but not consistently beneficial; observed adverse effects.
      • Vasopressin V2 receptor (V2R) antagonists (tolvaptan): reduce renal cAMP and cyst growth; TAMPO and ALADIN trials showed slowed eGFR decline; liver function impairment, polydipsia, and diarrhea are potential side effects; tolvaptan approved by FDA for rapidly progressing disease in some populations; ongoing evaluation in subgroups.
      • Somatostatin analogues (e.g., octreotide-LAR): lower cAMP via GPCRs; mixed efficacy data; cholecystitis as a possible side effect; some reports indicate reduced renal pain and slowed eGFR decline in certain trials.
      • Combination strategies: combining growth inhibitors may enhance efficacy and reduce adverse effects; genotype-imaging data may help select patients most likely to benefit from therapies like tolvaptan.
      • Other experimental approaches: miRNA targeting of PKD1/PKD2 regulation; caloric restriction and intermittent fasting being explored in overweight/obese individuals; preclinical studies in animals exploring Src, B-raf, CDK, STAT3/6, purinergic receptors, HGF receptor, glucosylceramide, PPARγ agonists, and miRNA-based therapies.
      • Metabolic reprogramming and time-restricted feeding shown to reduce cyst area, kidney fibrosis, inflammation in murine models; branched-chain amino acids may promote cyst growth in mice.
    • Autosomal recessive PKD (ARPKD)
    • Genetics and major gene: PKHD1; locus on chromosome 6p21.1–6p12.2; one of the largest genes (~450extkb450 ext{ kb}, ≥8686 exons); encodes fibrocystin/polyductin (FPC), which is ~40744074 amino acids long.
    • FPC structure and localization: a single transmembrane receptor-like protein with a large extracellular N-terminus; localized on primary cilia of cortical and medullary collecting ducts and bile duct cholangiocytes; also present on basal body and plasma membrane; interacts with PC2 and may participate in mechanosensory regulation, calcium signaling, PCP, and centrosome regulation during mitosis.
    • Clinical features: classic ARPKD diagnosed in utero or neonatally; markedly enlarged echogenic kidneys; oligohydramnios due to reduced fetal urine; high neonatal mortality (≈30 ext{%} die shortly after birth; ≈60 ext{%} within the first month).
    • Older-onset ARPKD: survivors may have systemic hypertension, progressive renal insufficiency, and liver disease (biliary dysgenesis with congenital hepatic fibrosis and Caroli disease) leading to portal hypertension.
    • Diagnosis and imaging: ultrasonography, CT, MRI show large echogenic kidneys with poor corticomedullary differentiation; macrocysts are uncommon at birth; prenatal diagnosis possible after ~2424 weeks gestation in severe cases.
    • Genetic testing: PKHD1 sequencing is challenging due to gene size and complexity; presymptomatic screening in at-risk family members is feasible and cost-effective when family mutations are known.
    • Tuberous sclerosis complex (TS) and Von Hippel–Lindau disease (VHL)
    • TS: autosomal dominant; mutations in TSC1 or TSC2; kidney involvement includes cysts, angiomyolipomas, and renal cell carcinoma; TSC2 is adjacent to PKD1; mTOR inhibitors (e.g., everolimus) are first-line for TS-associated kidney tumors and extra-renal manifestations.
    • VHL: autosomal dominant; VHL gene mutations regulate hypoxia pathways via HIF; kidney manifestations include bilateral cysts and RCC; annual imaging surveillance (CT or MRI) recommended; nephron-sparing surgery increasingly used; HIF-2α inhibitor belzutifan approved for VHL-associated RCC.
    • Other diseases with large kidney cysts and related growth disorders
    • Autosomal dominant tubulointerstitial kidney disease (ADTKD; formerly 'medullary cystic kidney disease')
      • Overall concept: progressive kidney failure with relatively benign urine sediment; cysts not always present.
      • ADTKD subtypes and genes:
      • MUC1 (ADTKD-MUC1, formerly MCKD I): mutations in MUC1 create a toxic neoprotein fragment; slowly progressive CKD in adulthood with minimal proteinuria; cysts uncommon.
      • UMOD (ADTKD-UMOD, MCKD II): mutations in uromodulin (Tamm–Horsfall protein); often with gout; UMOD also localizes to cilia and centrosomes; disease may be referred to as UAKD; many noncoding UMOD variants associated with modest CKD risk in general population.
      • REN, HNF1β, SEC61A1: rarer causes of ADTKD; histology shows interstitial fibrosis; genetic testing using panels is increasingly common but costly and complex.
      • Clinical implications: diagnosis relies on genetic testing; management focuses on uric acid–lowering therapy (e.g., allopurinol, febuxostat) and general CKD care.
    • Nephronophthisis (NPHP) and NPHP-related ciliopathies
      • AR inheritance; collectively among the most common inherited childhood kidney failure etiologies.
      • >90 genes identified; many ciliopathy features across various organs.
      • Core renal phenotype: tubulointerstitial fibrosis, corticomedullary cysts, progressive CKD; proteinuria often absent or mild; hypertension tends to be late.
      • Common NPHP genes include NPHP1-20, IQCB1, CEP290, GLIS2, RPGRIP1L, NEK8, SDCCAG8, TMEM67, TTC21B, among others.
      • Senior–Loken syndrome = NPHP with retinitis pigmentosa; Joubert syndrome may include NPHP as a component; Bardet–Biedl syndrome (BBS) is a ciliopathy with renal cysts among multisystem features (obesity, polydactyly, retinal dystrophy, etc.).
      • Genetic testing is increasingly straightforward with sequencing; no specific therapies exist beyond CKD management and treating systemic abnormalities.
    • Karyomegalic tubulointerstitial nephritis (KIN)
      • Extremely rare; an AR condition due to biallelic FAN1 mutations; histology shows karyomegaly and interstitial fibrosis/tubular atrophy.
    • Medullary sponge kidney (MSK)
      • Often sporadic; malformation with cystic dilatation of renal collecting ducts; usually benign and incidental; CT urography is less sensitive than IVP historically; MSK is associated with higher rates of calcium phosphate and calcium oxalate stones; stones treated like the general population; reduced concentrating ability and higher UTI risk common.
    • Congenital abnormalities of the kidney and urinary tract (CAKUT)
      • Etiologically heterogeneous; up to ~1 in 500500 live births may be affected.
      • Examples include kidney hypoplasia, agenesis, ureteropelvic junction obstruction, vesicoureteral reflux.
      • Can be sporadic or familial; a major contributor to pediatric CKD.
      • Genes implicated include EYA1, SIX1 (branchio-otorenal syndrome), PAX2 (renal coloboma syndrome).
      • Prenatal environmental factors (e.g., ACE inhibitors/ARBs exposure) can contribute to tubulogenesis defects.
    • Mitochondrial diseases affecting the kidney
      • Involves mitochondrial genome-encoded and nuclear-encoded components of the respiratory chain; maternally inherited mtDNA defects (13 mt-genome gene products) are complemented by nuclear DNA mutations.
      • Kidney involvement includes tubulointerstitial disease, proximal tubular defects (Fanconi syndrome), acidosis, hypophosphatemic rickets, hypercalciuria, glycosuria, tubular proteinuria, decreased concentrating ability; neuromuscular symptoms are common.
    • Diagnostic considerations and modern genomic approach
    • A shift toward large DNA sequencing panels (or whole-genome sequencing) to diagnose Mendelian kidney diseases, including those with cysts and growth abnormalities.
    • The traditional old nomenclature (e.g., MCKD, NPHP) is being replaced by genetically defined categories; genetic testing is essential for definitive diagnosis.
    • Global considerations
    • Mesoamerican nephropathy (MN): epidemic CKD in Central America (notably Nicaragua and El Salvador); high male predominance; lacks significant proteinuria, suggesting tubulointerstitial damage from toxins and heat stress; potential genetic predisposition.

  • Autosomal Dominant PKD (ADPKD): Etiology and pathogenic mechanisms (detailed)

    • ADPKD hallmark: progressive development of epithelial-lined cysts in kidneys; cysts originate from a small fraction of tubules but expansion leads to massive cyst burden and loss of normal renal tissue.
    • Core pathophysiology includes increased epithelial cell proliferation, enhanced fluid secretion, reduced differentiation, and altered extracellular matrix.
    • Genetic basis: PKD1 (major) and PKD2 (minor) account for ~85 ext{%} and ~15 ext{%} of cases, respectively; PKD1 mutations often yield more severe disease than PKD2, contributing to underdiagnosis of PKD2 variants.
    • Expression and localization of disease proteins
    • PC1 and PC2 co-localize to the primary cilium and other cellular compartments; the PC1/PC2 complex is involved in calcium signaling and mechanosensation.
    • The loss of ciliary function and downstream calcium/cAMP signaling is a central mechanistic theme in cystogenesis across ciliopathies.
    • Genomic features and two-hit model
    • ADPKD involves a germline PKD1/PKD2 mutation in every cell; cysts arise from cells with a somatic second hit, inactivating the remaining normal allele.
    • In mice, Pkd1 haploinsufficiency with proliferative context can initiate cystogenesis; a third perturbation may accelerate cyst formation.
    • Clinical features and variability
    • ADPKD affects all ethnic groups; prevalence estimated at 1:10001:1000 to 1:4001:400.
    • Disease penetrance is complete but expressivity is variable.
    • Typical age of symptom onset ranges from fetal life to late adulthood; hypertension may precede GFR decline and is a major driver of morbidity and mortality.
    • Intracranial aneurysms (ICA) occur 4–5× more frequently in ADPKD; family history is a risk factor; presymptomatic ICA screening by MR angiography may be considered in those with a positive family history.
    • Other vascular abnormalities: dolichoectasias and potential for stroke; valvular heart disease (mitral/tricuspid) is more common; diverticulae and abdominal wall hernias are also more frequent.
    • Diagnostic criteria and screening
    • Diagnosis typically relies on family history compatible with autosomal dominant inheritance plus bilateral multiple kidney cysts.
    • Renal ultrasonography is used for presymptomatic screening and donor evaluation in ADPKD families.
    • Age-stratified ultrasound criteria for at-risk relatives:
      • Age 15–29: at least two cysts (in one or both kidneys) with sensitivity Se=0.96Se = 0.96 and specificity Sp=1.00Sp = 1.00 (i.e., 96% and 100%).
      • Age 30–59: at least two cysts in each kidney and at least four cysts in each kidney for age ≥60: Se and Sp both 1.001.00.
      • Absence of at least two cysts in each kidney in ages 30–59 effectively excludes disease with a false-negative rate of 0 ext{%}}, though PKD2 mutations may present later and reduce sensitivity."
    • Cross-sectional imaging (CT, T2-MRI) can detect smaller cysts; however, CT carries radiation risk and gadolinium-enhanced MRI has renal safety considerations.
    • Genetic testing is available but PKD1 mutational analysis is technically challenging due to duplicated regions; newer sequencing approaches are improving sensitivity and cost.
    • Treatment and disease-modifying strategies (ADPKD)
    • No approved disease-modifying therapy that universally halts cyst growth; management focuses on cardiovascular risk reduction and symptom control.
    • Hypertension management: target blood pressure around 140/90 mmHg140/90\ \text{mmHg}; overly aggressive BP control (e.g., very low SBP) may worsen renal perfusion and accelerate progression in some patients.
    • Cyst infection treatment: lipophilic antibiotics with good cyst penetration; longer courses (4–6 weeks) are often necessary.
    • Renal stone management: hydration and analgesia; uric acid stones are common in ADPKD; consider metabolic assessment for stone risk.
    • Pain management from enlarged kidneys: nonnarcotic and narcotic analgesics; nonpharmacologic approaches; cyst decompression in select cases.
    • Renal replacement therapy and transplantation: many patients reach ESRD; PD may be challenging with massively enlarged kidneys; nephrectomy may be needed pretransplant in some cases to accommodate the graft and alleviate pain.
    • Targeted therapies tested in trials:
      • mTOR inhibitors (sirolimus, everolimus) have not demonstrated consistent clinical benefit for most patients.
      • V2R antagonists (tolvaptan) reduce cyst growth by lowering renal cAMP; trials (TAMPO, ALADIN) showed slowed decline in renal function; side effects include liver enzyme abnormalities, polydipsia, diarrhea; FDA has approved tolvaptan for rapidly progressing disease in selected patients.
      • Somatostatin analogues (octreotide-LAR) reduce cAMP via GPCRs; trials show mixed results; potential cholecystitis risk; may slow eGFR decline in some cohorts.
      • Dipka (DIPAK) studies suggest nerve block may relieve chronic refractory pain in ADPKD.
      • Combination therapies and individualized approaches: combining growth inhibitors may improve efficacy and tolerate side effects; genetic and imaging data may help in patient selection for tolvaptan and other therapies.
      • Other investigative avenues (preclinical/early phase): targeting microRNAs regulating PKD1/PKD2 expression; metabolic interventions (caloric restriction, time-restricted feeding); investigating signaling kinases (Src, B-RAF, CDK), STAT3/6, purinergic receptors, HGF receptor, glucosylceramide signaling, PPARγ agonists; and exploring miRNA-based strategies.
    • Autosomal Recessive PKD (ARPKD): Etiology, clinical features, diagnosis, and management
    • PKHD1 is the sole major gene; encodes fibrocystin/polyductin (FPC).
    • FPC (~40744074 amino acids) is a receptor-like protein localized to primary cilia and basal body; interacts with PC2 and may regulate mechanosensation, calcium signaling, PCP, and centrosome duplication.
    • Classic ARPKD presentation: enlarged echogenic kidneys in fetuses/neonates; oligohydramnios; significant neonatal mortality; systemic hypertension and progressive renal failure in later life; concomitant liver disease (CHF and Caroli disease) with risk of portal hypertension.
    • Diagnosis: imaging (US, CT, MRI); prenatal detection possible after 24 weeks; macrocysts are not common at birth; ultrasound helps distinguish ARPKD from ADPKD in older individuals by absence of parental cysts.
    • Molecular diagnosis: PKHD1 sequencing challenging due to size; presymptomatic screening of at-risk relatives is straightforward if familial mutations are known.
    • Treatment and prognosis: no disease-specific therapy; supportive care with neonatal ICU, blood pressure control, dialysis, and transplantation improves survival; liver disease may necessitate liver transplant; Caroli disease may require porto-systemic shunting.
    • Tolvaptan in ARPKD: AAV/v2 blockade that showed promise in preclinical PKD models; phase 3 trials are evaluating safety and efficacy in infants and children.
    • Other diseases characterized by large kidney cysts and renal growth disorders
    • Autosomal dominant tubulointerstitial kidney disease (ADTKD) and related entities (MCKD, UMOD-REN-HNF1β-Sec61A1 spectrum)
      • ADTKD presents with progressive CKD and relatively benign urine sediment; cysts are not always present.
      • UMOD (MCKD II): uromodulin mutations; gout association; UMOD localizes to cilia and centrosomes; MCKD II associated diseases (familial juvenile hyperuricemic nephropathy, glomerulocystic kidney disease) and UAKD terminology emphasize overlapping features.
      • MUC1 (ADTKD-MUC1): toxic neoprotein fragment; slowly progressive CKD; minimal proteinuria; fibrosis and tubular atrophy on histology; disease recurs after transplant is not typical.
      • Other ADTKD genes include REN, HNF1β, SEC61A1; gene panel testing is increasingly used for diagnosis.
    • Nephronophthisis (NPHP) and Bardet–Biedl syndrome (BBS)
      • NPHP: AR ciliopathies with tubulointerstitial fibrosis and corticomedullary cysts; early-onset CKD common in childhood; hypertension often late; multiple NPHP genes (NPHP1-20, IQCB1, CEP290, GLIS2, RPGRIP1L, NEK8, SDCCAG8, TMEM67, TTC21B).
      • Senior–Loken: NPHP with retinitis pigmentosa.
      • Joubert syndrome: cerebellar vermis hypoplasia; may include NPHP components.
      • BBS: multisystem ciliopathy with truncal obesity, cognitive impairment, retinal dystrophy, polydactyly, developmental anomalies; kidney cysts and NPHP-like kidney disease common; ≥26 BBS genes identified; autosomal recessive inheritance.
    • Other notable ciliopathies and tubulointerstitial diseases
      • Karyomegalic tubulointerstitial nephritis (FAN1 mutations; recessive).
      • Medullary sponge kidney (MSK): often sporadic, benign; tubular collecting duct malformation; higher risk of stones; diagnostic imaging challenges.
      • CAKUT spectrum: genetics increasingly recognized; environmental contributors (e.g., in utero exposure to ACE inhibitors) can cause tubulogenesis defects; PAX2 and EYA1/SIX1 as examples of CAKUT-related syndromes.
    • Mitochondrial disease and kidney involvement
      • Mitochondrial genome defects and nuclear-encoded mutations can cause tubulointerstitial disease, proximal tubule dysfunction (Fanconi), glycosuria, acidosis, hyperuricemia, and other manifestations; kidney disease is a recognized component of broader mitochondrial syndromes.

  • Key numerical and statistical references (illustrative):

    • ADPKD global prevalence: 1:1000extto1:4001:1000 ext{ to } 1:400
    • ADPKD lifetime number affected: extaround12,000,000ext{around } 12{,}000{,}000 people worldwide
    • Ultrasound diagnostic criteria for at-risk relatives (age-specific): Se/Sp values as cited above (e.g., Se ≈ 0.960.96, Sp = 1.00 for ages 15–29; Se = Sp = 1.00 for ages 30–59 and ≥60)
    • ADPKD progressively enlarges kidneys: up to ~ fourfold length increase and up to ~20× weight

  • Practical implications for exam preparation

    • Understand the concept of ciliopathies and how primary cilia defects connect various cystic kidney diseases.
    • Be able to distinguish ADPKD vs ARPKD by gene, inheritance, age of onset, kidney and liver manifestations, and diagnostic modalities.
    • Recognize the two-hit model for cystogenesis in ADPKD and the role of somatic second hits in clonal expansion.
    • Know the key ADPKD therapeutic strategies, their mechanisms (cAMP/PKA pathway, mTOR, and GPCR signaling), and major trial evidence (tolvaptan, mTOR inhibitors, somatostatin analogues); understand FDA indications and safety considerations.
    • Differentiate ADTKD subtypes (MUC1, UMOD, REN, HNF1B, SEC61A1) and their clinical features (glycation, gout, hyperuricemia, tubulointerstitial fibrosis).
    • For ARPKD, remember the PKHD1 gene, FPC protein, neonatal vs pediatric presentation, hepatic involvement, and the potential role of tolvaptan.
    • Review non-PKD tubulointerstitial diseases (MCKD/ADTKD, NPHP, MSK, CAKUT, mitochondrial disease) and how genetic testing informs diagnosis and management.

  • Connections to clinical practice and real-world relevance

    • Genetic testing panels and whole-genome sequencing are increasingly central to diagnosing kidney diseases of unknown etiology, guiding prognosis and potential enrollment in targeted trials.
    • Surveillance strategies for associated conditions (ICA screening in ADPKD with positive family history; RCC surveillance in TS/VHL; nephron-sparing surgery in VHL) reflect holistic care across organ systems.
    • Understanding ciliopathy pathways informs both diagnostics and potential therapeutics (e.g., targeting ciliary signaling, GPCR pathways, mTOR, or PKA/cAMP signaling).

  • Ethical, philosophical, and practical implications

    • Genetic testing raises considerations about predictive testing in at-risk relatives, especially for adult-onset diseases with variable penetrance and pleiotropy.
    • Family planning and counseling are important given autosomal dominant and autosomal recessive inheritance patterns and potential prenatal diagnoses.
    • Access to expensive targeted therapies (e.g., tolvaptan) requires careful patient selection and consideration of cost-benefit and quality-of-life impacts.

  • Summary of key terms and concepts (glossary-style)

    • PKD1, PKD2: genes encoding PC1 and PC2; major drivers of ADPKD.
    • PC1/PC2: polycystin receptor–channel complex; mechanosensitive, calcium-regulating in cilia.
    • cAMP, PKA: central second messenger pathway implicated in cyst growth; V2R antagonists reduce cyst growth by lowering cAMP.
    • ADTKD: autosomal dominant tubulointerstitial kidney disease; nephronophthisis-related and UMOD/REN/MUC1-related diseases.
    • NPHP: nephronophthisis; ciliopathy with corticomedullary cysts and tubulointerstitial fibrosis; many genes identified.
    • CAKUT: congenital abnormalities of kidney and urinary tract; genetically heterogeneous; examples include PAX2, EYA1, SIX1.
    • MSI, MSK, MCKD: various cystic kidney diseases with distinct genetic and clinical features.
    • Belzutifan: HIF-2α inhibitor approved for VHL-associated RCC.

  • References and further reading (as context)

    • Cornec-Le Gall E et al.: Autosomal dominant polycystic kidney disease. Lancet 2019.
    • Devuyst O et al.: Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers 2019.
    • Vivante A, Hildebrandt F: Exploring the genetic basis of early-onset CKD. Nat Rev Nephrol 2016.
    • Zhou J: Polycystins and primary cilia: primers for cell cycle progression. Annu Rev Physiol 2009.

Note: The content above condenses and reorganizes the material from the provided transcript into study-friendly notes with emphasis on mechanisms, genetics, clinical features, diagnosis, and treatment/management. All numerical values, gene names, and key concepts are taken directly from the source material as presented.